The long-term lung effects of COVID-19 remain an evolving area of respiratory medicine, as many patients continue to experience persistent or delayed complications even after recovery from the acute infection. Post-COVID conditions often include reduced lung function, chronic cough, breathlessness, fatigue, and radiological evidence of scarring or fibrosis. These changes are particularly prominent in patients who endured severe disease, required mechanical ventilation, or developed acute respiratory distress syndrome. Emerging studies also suggest microvascular injury and immune dysregulation contribute to lingering respiratory impairment, raising concerns about the potential for progressive lung disease in certain individuals.
Managing the long-term lung effects of COVID-19 requires multidisciplinary care, combining pulmonology, rehabilitation, and primary care expertise. Pulmonary function testing, imaging, and biomarker monitoring guide individualized assessment and treatment planning. Interventions may include pulmonary rehabilitation, oxygen supplementation, anti-fibrotic therapy in selected patients, and management of comorbid conditions such as cardiovascular disease or diabetes. Patient education on self-monitoring, lifestyle modification, and vaccination plays an important role in long-term recovery. Continued research into the pathophysiology of post-COVID lung changes is helping to shape novel therapeutic approaches, ensuring that care evolves alongside new evidence.
Title : Global warming and increasing respiratory illnesses
Yazdan Mirzanejad, University of British Columbia, Canada
Title :
Saurabh Chattopadhyay, University of Kentucky, United States
Title : Risk factors for mycobacterium avium complex infections in patients with chronic obstructive pulmonary disease
Alizaman Sadigov, Medical University, United States
Title : Managing integration and interoperability in transformed pulmonology, respiratory medicine and lung health ecosystems
Bernd Blobel, University of Regensburg, Germany
Title : Personalized and Precision Oncology (PPO) to be set up via precision oncology strategy for cancer care team: Developing targeted lung cancer therapy and advancing personalized cancer care
Sergey Suchkov, N.D. Zelinskii Institute for Organic Chemistry of the Russian Academy of Sciences & InMedStar, Russian Federation
Title : Advancements in pulmonology and respiratory care through the view of Personalized and Precision Medicine (PPM) and biodesign-driven translational applications
Sergey Suchkov, N.D. Zelinskii Institute for Organic Chemistry of the Russian Academy of Sciences & InMedStar, Russian Federation